(Q43234592)

16 November 2017

title

New pharmacological developments in the treatment of hepatocellular cancer (English)

1 reference

16 November 2017

0 references

6

Jaffer A Ajani

1 reference

16 November 2017

Niraj J Gusani

1

1 reference

16 November 2017

Yixing Jiang

2

1 reference

16 November 2017

Eric T Kimchi

3

1 reference

16 November 2017

Kevin F Staveley-O'Carroll

4

1 reference

16 November 2017

Hua Cheng

5

1 reference

16 November 2017

language of work or name

1 reference

1 January 2009

1 reference

16 November 2017

number of pages

8

1 reference

inferred from page(s)

published in

Drugs

1 reference

16 November 2017

volume

69

1 reference

16 November 2017

issue

18

1 reference

16 November 2017

page(s)

2533-2540

1 reference

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

16 November 2017

cites work

1 reference

12 December 2020

Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease

1 reference

12 December 2020

Significance of circulating endothelial progenitor cells in hepatocellular carcinoma

1 reference

12 December 2020

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

12 December 2020

Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver.

1 reference

12 December 2020

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

1 reference

12 December 2020

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

1 reference

12 December 2020

An analysis of 412 cases of hepatocellular carcinoma at a Western center

1 reference

12 December 2020

Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha

1 reference

12 December 2020

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

1 reference

12 December 2020

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

1 reference

12 December 2020

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

1 reference

12 December 2020

Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis

1 reference

12 December 2020

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

1 reference

12 December 2020

Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor

1 reference

12 December 2020

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

1 reference

12 December 2020

Hepatic resection versus transplantation for hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration

1 reference

12 December 2020

Updated treatment approach to hepatocellular carcinoma.

1 reference

12 December 2020

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

12 December 2020

Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma

1 reference

12 December 2020

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

12 December 2020

Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma

1 reference

12 December 2020

Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene.

1 reference

12 December 2020

Evolution of systemic therapy of advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

12 December 2020

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma

1 reference

12 December 2020

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor.

1 reference

12 December 2020

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

12 December 2020

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

12 December 2020

Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas

1 reference

12 December 2020

Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years

1 reference

12 December 2020

Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma

1 reference

12 December 2020

Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.

1 reference

12 December 2020

Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas

1 reference

12 December 2020

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

1 reference

12 December 2020

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

1 reference

12 December 2020

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

1 reference

12 December 2020

Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma

1 reference

12 December 2020

Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice

1 reference

12 December 2020

Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas

1 reference

12 December 2020

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.2165/11530870-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

16 November 2017

1013182893

0 references

1 reference